Patent Cooperation Treaty

ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder

Retrieved on: 
Thursday, May 4, 2023
Patent, Major depressive disorder, Norepinephrine transporter, United States patent law, NET, Patent Cooperation Treaty, EOP, Phase II, CNS, PCT, Norepinephrine, MDD, Ophthalmology, European, FDA, Treatment, Pharmaceutical industry

FREMONT, CA, May 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it received a US patent certificate, US 11,554,154 B2, for PDC-1421, for the treatment of Major Depressive Disorder (MDD) on April 25, 2023.

Key Points: 
  • FREMONT, CA, May 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it received a US patent certificate, US 11,554,154 B2, for PDC-1421, for the treatment of Major Depressive Disorder (MDD) on April 25, 2023.
  • The patent application was submitted to the US Patent and Trademark Office (USPTO) on July 22, 2020, under the title of “Polygala Extract for the Treatment of Major Depressive Disorder.” The invention relates to a method for treating Major Depressive Disorder by orally administering a composition containing a Radix Polygalae (Polygala tenuifolia Willd.)
  • PDC-1421 is a drug product of ABV-1504 that can be prepared into a gelatin capsule for oral administration.
  • The patent was also submitted for Patent Cooperation Treaty (PCT) and subsequently filed in several countries, including the European Union, China, Japan in 2022.

MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy

Retrieved on: 
Tuesday, May 2, 2023
Biotechnology, General Health, Mental Health, Health, Pharmaceutical, FOR, PFE, DRS, Patent Cooperation Treaty, Annual general meeting, Acquisition, Patient, Patent, Investment, Risk, Financial management, NYSE, FCM, GAD, GW Pharmaceuticals, Research, DSM-IV codes, Aerie Pharmaceuticals, FDA, Mental health, Social media, NOT, ALC, ALL, Annual Meetings of the International Monetary Fund and the World Bank Group, Multimedia, LSD, Trustee, NEO, MindMed, Drug development, SG, Spectrum, Clinical trial, Pfizer, Celgene, RBC Capital Markets, Invention, Jazz Pharmaceuticals, EF Hutton, Psychiatry, Management, Auction, Security (finance), Pharmaceutical industry, Medical device, Alcon, ADHD

The Company has launched www.ProtectMindMed.com to keep shareholders up to date on key developments leading up to the Annual Meeting.

Key Points: 
  • The Company has launched www.ProtectMindMed.com to keep shareholders up to date on key developments leading up to the Annual Meeting.
  • The full text of the Board’s letter to shareholders, which can be viewed and downloaded here , follows:
    Thank you for your investment in MindMed.
  • Your vote at the Company’s 2023 Annual General Meeting of Shareholders, scheduled for June 15, 2023, is critically important this year.
  • Shareholders will receive proxy materials directly via the preferred method, hard copy or email, specific to each shareholder’s account.

Lightbridge Receives Notice of Allowance for Key Patent in the United States for its Innovative Nuclear Fuel Assemblies

Retrieved on: 
Tuesday, May 2, 2023
Patent, Rib, United States Patent and Trademark Office, Patent Cooperation Treaty, PCT, LTBR, Growth, Economics, Safety, Uranium mining, Thanasis Lightbridge

RESTON, Va., May 02, 2023 (GLOBE NEWSWIRE) -- Lightbridge Corporation (Nasdaq: LTBR), an advanced nuclear fuel technology company, today announced that it received a Notice of Allowance for a key divisional patent from the United States Patent and Trademark Office related to Lightbridge’s innovative metallic nuclear fuel assemblies.

Key Points: 
  • RESTON, Va., May 02, 2023 (GLOBE NEWSWIRE) -- Lightbridge Corporation (Nasdaq: LTBR), an advanced nuclear fuel technology company, today announced that it received a Notice of Allowance for a key divisional patent from the United States Patent and Trademark Office related to Lightbridge’s innovative metallic nuclear fuel assemblies.
  • This is a divisional application based on a 2011 Patent Cooperation Treaty (PCT) application.
  • Seth Grae, President and CEO of Lightbridge, commented: “We are proud to add this latest Notice of Allowance to our growing portfolio of intellectual property that supports our strategy to commercialize Lightbridge Fuel™ in the United States.
  • Lightbridge has patents pending in various countries around the world, including the United States, South Korea, Canada, Japan, Eurasia, and Australia, as well as additional patents pending in Europe and China.

U.S. Patent filed by BYND Cannasoft to Expand its Artificial Intelligence and Machine Learning Algorithm to a Male Treatment Device

Retrieved on: 
Thursday, April 27, 2023
Male, CSE, Prevalence, Investment, HIV, A.I, Woman, BYND, Patent Cooperation Treaty, PCT, Invention, BCAN, Non-governmental organization, Machine learning, Algorithm, Application virtualization, HIV/AIDS, Artificial intelligence, Female, Television

ASHKELON, Israel and VANCOUVER, British Columbia, April 27, 2023 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) ("BYND Cannasoft" or the "Company") announced today that its Zigi Carmel Initiatives & Investments LTD. subsidiary filed U.S. Provisional Patent Application 63461609 on April 25, 2023, covering the mechanical structure, operation, and controlling aspects of a male treatment device for external use capable of gathering information and creating custom programs according to the collected data from the sensors and uploading the data to the cloud. This U.S. Provisional Patent Application marks BYND Cannasoft's third potential candidate that could introduce new advanced haptic experiences to the fast-growing sexual wellness and sextech market.

Key Points: 
  • The male treatment device utilizes artificial intelligence and machine learning algorithms to control its operational parameters based on the user's physiological parameters.
  • Provisional Patent Application number 63450503 covering the mechanical structure, operation, and controlling aspects of its smart female treatment device.
  • BYND Cannasoft intends to file a similar application with the PCT for its male treatment device.
  • BYND Cannasoft plans to develop this A.I.-based smart treatment device for men, its A.I.-based smart treatment device for women, and its EZ-G device.

The Patent Cooperation Treaty (PCT) Provides Positive Opinion on BYND Cannasoft’s AI-Based Female Treatment Device

Retrieved on: 
Tuesday, April 25, 2023
Pressure, Communication, CSE, Female, Feedback, China International Search and Rescue Team, ISR, Examination, BYND, Temperature, Patent Cooperation Treaty, PCT, USD, BCAN, US, Patent, Machine learning, Algorithm, Pain management, Artificial intelligence, AI, Fluid mechanics, Heart rate, Medical device, Pharmaceutical industry

ASHKELON, Israel and VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) ("BYND Cannasoft" or the "Company") announced today it has received a positive opinion from the Patent Cooperation Treaty (PCT) for its Artificial Intelligence (AI) Sex Tech-based Female Treatment Device.

Key Points: 
  • ASHKELON, Israel and VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) ("BYND Cannasoft" or the "Company") announced today it has received a positive opinion from the Patent Cooperation Treaty (PCT) for its Artificial Intelligence (AI) Sex Tech-based Female Treatment Device.
  • By collecting data from its sensors, the device will adjust stimulation patterns and determine the lubricant dispensing rate, thereby facilitating sexual climax.
  • Should BYND Cannasoft receive a patent from the PCT, it can benefit in several ways:
    Global Protection: A PCT patent application protects in all PCT member countries.
  • Time to Decide: The PCT process provides a company additional time to decide in which countries to pursue patent protection.

Several Scientific Journals Publish Research by Herbalife Scientists Highlighting Global Product Testing Standards

Retrieved on: 
Monday, April 24, 2023
Research, Vitamins, Supplements, Other Retail, Fitness & Nutrition, Specialty, General Health, Health, Retail, Science, Other Science, Taste, Multiplex polymerase chain reaction, Validation, Herbal medicine, Direct electron ionization liquid chromatography–mass spectrometry interface, Composition, Integrated DNA Technologies, Patent Cooperation Treaty, Spectrometry, Chinese University of Hong Kong, PCT, Quality, Open access, Food industry, Walker Process Equipment, Inc. v. Food Machinery & Chemical Corp., Patent, Manuscript, MDPI, Master of Science, Medicine, Open Access Scholarly Publishing Association, Quality assurance, Control, Education minister, Accuracy and precision, Content, Safety, Dietary supplement, Book, Standardization, Herbalife, Food

Premier wellness company and community, Herbalife, announced today that five recent research studies by its team of Quality Assurance scientists have been published across several international peer-reviewed journals.

Key Points: 
  • Premier wellness company and community, Herbalife, announced today that five recent research studies by its team of Quality Assurance scientists have been published across several international peer-reviewed journals.
  • The articles share the company’s best practices in validating herbal ingredients, identifying compound sampling techniques and other processes involved in the rigorous testing that goes into Herbalife products around the world.
  • The acceptance and publication of these studies underscore the global nutrition company’s commitment to scientific research, transparency, and accountability, driving consumer confidence and helping people live their best lives.
  • Herbalife products, quality assurance and manufacturing processes have received numerous international awards attesting to its high-quality standards.

Vivos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, March 30, 2023
Nexus, AFD, Insurance, Temporomandibular joint dysfunction, DNA, Intellectual property, ASC, SEC filing, International, TMD, DME, Classification, COVID-19, Patent Cooperation Treaty, DSO, OSA, Sale, Snoring, Pain, Organization, Dentist, Acquisition, Dental Service Organizations, Patent, Patient, Annual report, Webcast, Growth, Security (finance), FDA, Durable medical equipment, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, Sleep, Food, VIP, Pharmaceutical industry, Cryptocurrency, Video game, Vivos, Bruxism

LITTLETON, Colo., March 30, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing related sleep disorders in adults, including mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today reported financial results and operating highlights for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • As of December 31 2022, patients treated with The Vivos Method totaled over 33,000, compared to approximately 25,000 as of the end of 2021.
  • The full 10-K report will be available on the SEC Filings section of the Investor Relations section of Vivos’ website at https://vivos.com/investor-relations .
  • A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations .
  • An online archive of the webcast will be available on the Company’s website for 30 days following the call.

GBT’s 3D, Multiplanar Integrated Circuit Architecture Patent in Korea - Granted

Retrieved on: 
Thursday, March 30, 2023
Patent, Samsung Electronics, LG Electronics, Digital, United States Patent and Trademark Office, 3D, SK Hynix, Electronics, Research, Patent Cooperation Treaty, ICS, PCT, Computer, Government, CPU, Investment, SAN, OTC, MP, GBT, Architecture, Silicon, AI, GPU, Video game

South Korea is a significant player in the semiconductor industry, with its industry being one of the country's most successful sectors.

Key Points: 
  • South Korea is a significant player in the semiconductor industry, with its industry being one of the country's most successful sectors.
  • South Korea is home to some of the world's largest semiconductor manufacturers, including Samsung Electronics, SK Hynix and LG Electronics.
  • GBT’s patent for its 3D, MP microchip architecture presents a new way to design and manufacture immense size integrated circuits to fit advanced analog, digital and mixed type integrated circuits (ICs) on a silicon wafer.
  • The Company’s first 3D microchip patent was filed on March 5, 2019, and granted as of December 1, 2020, by the United States Patent and Trademark Office (“USPTO”); U.S. Patent No.

NurExone Announces Q4 and Full-year 2022 Financial Results and Provides Company Update, Highlighting 143.9% Scientific Research Investment Growth

Retrieved on: 
Thursday, March 30, 2023
Patent, Rat, Reflex, TSX Venture Exchange, Central nervous system, Tetraplegia, United States Patent and Trademark Office, Spinal cord, Frankfurt Stock Exchange, Policy, Exosome, CAD, FSE, Research, Scientific Outlook on Development, Patent Cooperation Treaty, PCT, NRX, Small RNA, TEL, Acquisition, Patient, PTEN, The Company, SCI, Pharmaceutical industry, Cryptocurrency, Medical device

During the year, the Company's cash increased by 11.1%, from US$2.21 million in 2021 to US$2.46 million in 2022.

Key Points: 
  • During the year, the Company's cash increased by 11.1%, from US$2.21 million in 2021 to US$2.46 million in 2022.
  • In Q4 2022, research and development expenses amounted to US$0.38 million, compared to US$0.30 million for the same period in 2021.
  • Financial expenses grew from US$0.01 million in Q4 2021 to US$0.17 million in Q4 2022, due to a change in accounting policy for warrant derivatives.
  • As the Company scales, NurExone intends to continue expanding its patent portfolio in order to strengthen its competitive strength.

Patent Application Published for PharmAla Biotech’s MDMA Analogs

Retrieved on: 
Thursday, February 23, 2023
Clinical trial, UAMS, Safety, Pharmacology, University, Toxicology, Research, CSE, ABA, University of Arkansas School of Law, GMP, NCE, Hyperthermia, MDMA, Cardiotoxicity, PCT, Medicine, ALA, Patent Cooperation Treaty, MBDB, Pharmaceutical industry, Dietary supplement

VANCOUVER, British Columbia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) is pleased to announce the publication of a key Patent Cooperation Treaty (PCT) application containing 6 Novel Chemical Entities (NCEs).

Key Points: 
  • VANCOUVER, British Columbia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) is pleased to announce the publication of a key Patent Cooperation Treaty (PCT) application containing 6 Novel Chemical Entities (NCEs).
  • The application claims priority to and benefit of a United States provisional patent application filed on August 20, 2021.
  • This PCT application disclosed novel compositions of MDMA and analogs thereof, which may be used to alleviate the known side effects of MDMA while retaining its efficacy.
  • The PharmAla Patent Application also countenances the composition of 3 novel compositions of 1,3-benzodioxolyl-N-methylbutanamine (MBDB), a lesser-known analog of MDMA, which also presents an improved toxicology profile based on animal models; PharmAla refers to these compositions as the ABA series.